Company profile
Castle Biosciences, Inc.
NASDAQ: CSTL · Healthcare · Medical - Diagnostics & Research
#238 of 1,418 Healthcare companies by revenue46th-percentile growth
EA Score
70BFH 72DQ 70GM 66SS 67
v0.1 · 65/100 weight · provisional
↑ filing timeliness, workforce scale · ↓ listing tenure, revenue growth (YoY)
Methodology →Revenue TTM
$339.9M
Rev growth YoY (TTM)
-2.1%
Net income (FY)
-$24.2M
Employees
1,002
as of 2026-08-11
Market cap
$988.3M
as of 2026-08-11
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$344.2M$344.2M2025
Net income-$24.2M-$24.2M2025
Operating income-$42.8M-$42.8M2025
Total assets$578.6M$578.6M2025
Liabilities$107.7M$107.7M2025
Equity$470.9M$470.9M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Dermatologic100%
By geography
Not disclosed.
The read
What is Castle Biosciences, Inc.’s revenue?
Castle Biosciences, Inc. booked $344.2M in FY2025 revenue, growing 3.7% year over year — about the middle of the pack among Healthcare companies we track, at a -7.0% net margin.
Peers · Healthcare
Atea Pharmaceuticals, Inc.47DMannKind Corporation69BTruBridge, Inc.75B+Tactile Systems Technology, Inc.83B+Fulgent Genetics, Inc.68BDocGo Inc.44DNeighbors
Galveston →Key facts
CEODerek J. Maetzold
SectorHealthcare
IndustryMedical - Diagnostics & Research
HeadquartersFriendswood, TX
ExchangeNASDAQ: CSTL
Employees1,002
IPO date2019-07-25
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.